Nanobiotix completes $113.3 million IPO on Nasdaq
Client(s) Nanobiotix
Jones Day represented Nanobiotix S.A., a French clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, in connection with its $113.3 million initial public offering in the United States and listing on Nasdaq.